Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Moodys
Merck
McKinsey
Harvard Business School

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR TD-9855


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for TD-9855

Trial ID Title Status Sponsor Phase Summary
NCT01458340 ↗ A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed Theravance Biopharma Phase 2 The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
NCT01458340 ↗ A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed Theravance Biopharma R & D, Inc. Phase 2 The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
NCT01693692 ↗ Phase 2 Study of TD-9855 to Treat Fibromyalgia Completed Theravance Biopharma Phase 2 The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
NCT01693692 ↗ Phase 2 Study of TD-9855 to Treat Fibromyalgia Completed Theravance Biopharma R & D, Inc. Phase 2 The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
NCT01924143 ↗ TD-9855 Mass Balance Study Completed Theravance Biopharma Phase 1 The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
NCT01924143 ↗ TD-9855 Mass Balance Study Completed Theravance Biopharma R & D, Inc. Phase 1 The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
NCT02705755 ↗ TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Completed Theravance Biopharma Phase 2 This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for TD-9855

Condition Name

Condition Name for
Intervention Trials
Symptomatic Neurogenic Orthostatic Hypotension 3
ADHD 2
Fibromyalgia 2
Parkinson Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Pure Autonomic Failure 4
Hypotension, Orthostatic 4
Hypotension 4
Myofascial Pain Syndromes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TD-9855

Trials by Country

Trials by Country for
Location Trials
United States 89
United Kingdom 10
Australia 10
Spain 9
Canada 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Tennessee 6
New York 6
Florida 6
California 5
Washington 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TD-9855

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 3
Phase 2 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 7
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TD-9855

Sponsor Name

Sponsor Name for
Sponsor Trials
Theravance Biopharma 9
Theravance Biopharma R & D, Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Colorcon
AstraZeneca
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.